Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Clinical trial NCT02191891 · COMPLETED
Trial details
- NCT number
- NCT02191891
- Sponsor
- Boehringer Ingelheim
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-10-21
- Primary completion
- 2018-04-18
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.